Do complex sequences show an impact on titer, proper assembly, and purification?

Do you face issues in the interplay between off-target effects, target affinity, specificity, and patient safety?

Can you use standard analytics platforms for complex/non-standard molecule formats?

Do you adapt the functional assay panel to address complex modes of action with multiple targets?

Do you use a phase-specific approach to balance complex MoA and the timing of when functional assays are developed?